MORRA, FRANCESCO
MORRA, FRANCESCO
Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS
A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
2022 Criscuolo, Daniela; Morra, Francesco; Celetti, Angela
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
2022 Morra, Francesco; Merolla, Francesco; Damia, Giovanna; Ricci, Francesca; Varricchio, Silvia; Ilardi, Gennaro; Arenare, Laura; Califano, Daniela; Napolitano, Virginia; Fruscio, Robert; Melillo, Rosa Marina; Palazzo, Luca; Celetti, Angela
Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer
2022 Miro, Caterina; Di Giovanni, Angelo; Murolo, Melania; Cicatiello, Annunziata Gaetana; Nappi, Annarita; Sagliocchi, Serena; Di Cicco, Emery; Morra, Francesco; Celetti, Angela; Pacifico, Francesco; Imbimbo, Ciro; Crocetto, Felice; Dentice, Monica
The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis
2021 Morra, Francesco; Merolla, Francesco; Zito Marino, Federica; Catalano, Rosaria; Franco, Renato; Chieffi, Paolo; Celetti, Angela
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology
2019 Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A.
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
2019 Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A.
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic
2016 Cerrato, A; Morra, F; Celetti, A
New therapeutic perspectives in CCDC6 deficient lung cancer cells
2015 Morra F.; Luise C.; Visconti R.; Staibano S.; Merolla F.; Ilardi G.; Guggino G.; Paladino S.; Sarnataro D.; Franco R.; Monaco R.; Zitomarino F.; Pacelli R.; Monaco G.; Rocco G.; Cerrato A.; Linardopoulos S.; Muller M.T.; Celetti A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options | 1-gen-2022 | Criscuolo, Daniela; Morra, Francesco; Celetti, Angela | |
| The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma | 1-gen-2022 | Morra, Francesco; Merolla, Francesco; Damia, Giovanna; Ricci, Francesca; Varricchio, Silvia; Ilardi, Gennaro; Arenare, Laura; Califano, Daniela; Napolitano, Virginia; Fruscio, Robert; Melillo, Rosa Marina; Palazzo, Luca; Celetti, Angela | |
| Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer | 1-gen-2022 | Miro, Caterina; Di Giovanni, Angelo; Murolo, Melania; Cicatiello, Annunziata Gaetana; Nappi, Annarita; Sagliocchi, Serena; Di Cicco, Emery; Morra, Francesco; Celetti, Angela; Pacifico, Francesco; Imbimbo, Ciro; Crocetto, Felice; Dentice, Monica | |
| The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis | 1-gen-2021 | Morra, Francesco; Merolla, Francesco; Zito Marino, Federica; Catalano, Rosaria; Franco, Renato; Chieffi, Paolo; Celetti, Angela | |
| CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology | 1-gen-2019 | Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A. | |
| New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment | 1-gen-2019 | Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A. | |
| Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic | 1-gen-2016 | Cerrato, A; Morra, F; Celetti, A | |
| New therapeutic perspectives in CCDC6 deficient lung cancer cells | 1-gen-2015 | Morra F.; Luise C.; Visconti R.; Staibano S.; Merolla F.; Ilardi G.; Guggino G.; Paladino S.; Sarnataro D.; Franco R.; Monaco R.; Zitomarino F.; Pacelli R.; Monaco G.; Rocco G.; Cerrato A.; Linardopoulos S.; Muller M.T.; Celetti A. |